Morepen Laboratories Limited (MOREPENLAB)
Press Release
Press Release - Q2FY27
- Revenue Rs. 755 Cr +81% y-y; EBITDA Rs. 132 Cr +273% y-y; EBITDA margin 17.45% +897 bps y-y; PAT Rs. 89 Cr +117% y-y
- CDMO revenue Rs. 253 Cr, contributing 52% of combined API + CDMO revenue in Q2
- Exports Rs. 397 Cr +131% y-y; Medical Devices Rs. 208 Cr +65% y-y
- H1 FY27 revenue Rs. 1330 Cr +57% y-y; EBITDA Rs. 220 Cr +243% y-y; PAT Rs. 145 Cr +177% y-y
- API + CDMO capacity expanded to 614 KL; next phase to 800 KL by Q2 FY28
- ROCE improved to 18.8% TTM; receivable days reduced to 49; debt-to-equity 0.23x
- Submitted first U.S. ANDA for Sitagliptin Tablets USP during the quarter
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 MOREPENLAB — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add MOREPENLAB to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Morepen Laboratories Limited
Important.
The summary above is generated automatically from Morepen Laboratories Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.